

In collaboration with

ARCTR (Association de Recherche Clinique et  
Thérapeutique en Rhumatologie)

Association registered at the associations register of the  
Tribunal d'Instance of Strasbourg, vol.79 folio n°151.



With financial support of



www.atelierrc.com 04/15 - Ne pas jeter sur la voie publique; Photos : © istockphoto.com/lilly3/AlexRaths




A one-day symposium on lupus basic research and clinic



Journée Mondiale  
du Lupus 2015  
STRASBOURG - 10/11 MAI 2015

Forum  
of the faculty  
of medicine



Information:  
<http://jmls2015.sciencesconf.org>

**S**ystemic lupus erythematosus (SLE) represents a prototype of autoimmune rheumatic diseases. It is characterized by inflammation and damage of various tissues, including the joints, skin, kidneys, heart, lungs, blood vessels, and brain.

The etiology is multigenetic, hormonal (with a female prevalence) and environmental. It has been estimated that its average prevalence in France corresponds to 75 cases per 100,000 persons (currently 50,000 patients in France and 1.4 million individuals in the US). In its worst form, lupus can be fatal : 10% of patients die from kidney disease, cardiovascular disease or infections.

In France, in 2010, the SLE affected around 50 people out of 100 000 inhabitants and we evaluated the number of affected patients between 20 000 and 50 000. Some populations are more susceptible of being affected by the disease, which rarely occurs before the age of 5.

There is no specific treatment for the SLE at the moment. Some drugs, namely immunosuppressors and anti-inflammatories are usually used to ease the pain and reduce the symptoms. Nevertheless, it should be noted that, nowadays, some new therapeutic paths are suggested. These new approaches are more specific and generate less side-effects. Let's venture that they will considerably enhance the patients life quality.

Doctors, researchers, patients' associations and patients, this day is for you !

*Sylviane Muller & Jean Sibilia - February 2015*

## Programme

**10 mai 2015**

- 18:15**      **Opening session**  
**Sylviane Muller**, Strasbourg  
**Jean Sibilia**, Strasbourg
- The use of biologic drugs in SLE - has their time finally come?**  
**David Isenberg**, Londres
- 19:30/20:30**      **Welcome drink**  
**"Alsacian wine & kouglouf"**

**11 mai 2015**

- 09:00**      **How to treat severe lupus?**  
**Frédéric Houssiau**, Bruxelles
- 09:45**      **Implication of OX40L in SLE pathogenesis**  
**Patrick Blanco**, Bordeaux
- 10:30**      **Coffee break - visit poster and stands**
- 11:00**      **The potential role of neutrophils in lupus**  
**Marko Radic**, Memphis
- 11:45**      **New insights into the pathogenic role of Tfh and B cells in SLE**  
**Jacques-Eric Gottenberg**, Strasbourg
- Lymphocytes, autophagy and lupus**  
**Frédéric Gros**, Strasbourg
- 12:45**      **Buffet lunch - visit posters and stands**  
**Special lunch time: Parallel session for Patients and Associations**  
(Coordination by Anne-sophie Korganow and Christelle Sordet)
- 14:00**      **Nervous system disease in SLE: what we know and how to use it**  
**John Hanly**, Halifax
- 14:45**      **Infants born to mothers with Systemic Lupus**  
**Eric Hachulla**, Lille
- Functional genomics to dissect complex human lupus phenotype**  
**Pauline Soulas**, Strasbourg
- 15:45**      **Coffee break - visit posters and stands**
- 16:15**      **Etiopathogenesis of SLE: a 2015 update**  
**Alexis Mathian**, Paris
- 17:00**      **Ending words**  
**Sylviane Muller**, Strasbourg  
**Thierry Martin**, Strasbourg
- 17:30/20:00**      **Farewell drink**  
**"Wine & cheese"**